AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01268670
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive topical LET and oral oxycodone.
Trial: NCT02401269
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01015534
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01075789
Drug: Lignocaine
RxNorm normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
Trial: NCT01059656
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
Trial: NCT01932333
Drug: JNJ-40411813 50 mg
RxNorm normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
Trial: NCT01932333
Drug: JNJ-40411813 100 mg
RxNorm normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
Trial: NCT00931086
Drug: belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV 10mg/kg q28days
Trial: NCT00838526
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg capsule, taken orally, twice daily for 26 weeks.
Trial: NCT03447639
Drug: Povidone-iodine irrigation
RxNorm normalized name: povidone-iodine Irrigation Product
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
Trial: NCT01963741
Drug: leukotriene D4
RxNorm normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was \<30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
Trial: NCT01963741
Drug: histamine
RxNorm normalized name: Histamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was \<30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
Trial: NCT03352674
Drug: Insulin Glargine Ezelin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine (Ezelin) once daily at individually adjusted dose
Trial: NCT03352674
Drug: Insulin Glargine Pen Injector [Lantus]
RxNorm normalized name: insulin glargine Pen Injector [Lantus]
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine (Lantus) once daily at individually adjusted dose
Trial: NCT05046262
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium electroporation
Trial: NCT02860546
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Arm Only (of TAS 102 plus nivolumab)
Trial: NCT02860546
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One Arm Only (of TAS 102 plus nivolumab)
Trial: NCT02035371
Drug: Faster-acting insulin aspart
RxNorm normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose will be administered subcutaneously (s.c. under the skin)
Trial: NCT02035371
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose will be administered subcutaneously (s.c. under the skin)
Trial: NCT01132729
Drug: Valacyclovir Hydrochloride
RxNorm normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg caplet
Trial: NCT00842673
Drug: ST101
RxNorm normalized name: ST101 peptide
DrugBank: ST-101 (DB12621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg; administered once/day
Trial: NCT00842673
Drug: ST101
RxNorm normalized name: ST101 peptide
DrugBank: ST-101 (DB12621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg; administered once/day
Trial: NCT00842673
Drug: ST101
RxNorm normalized name: ST101 peptide
DrugBank: ST-101 (DB12621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg; administered once/day
Trial: NCT00122382
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
Trial: NCT01930682
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
Trial: NCT01927120
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
Trial: NCT01927120
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Trial: NCT01927120
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally on day -1. The dose for loading is 12 mg by mouth (PO)
Trial: NCT01099592
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not \< 8, the dose will increase to 40 mg.
Trial: NCT00748592
Drug: PD 0200390
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Trial: NCT00748592
Drug: PD 0200390
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Trial: NCT00748592
Drug: PD 0200390
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Trial: NCT02205463
Drug: KD019
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04935541
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
Trial: NCT01288079
Drug: TC-5214
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral, twice daily for 8 weeks
Trial: NCT01288079
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, oral, once daily
Trial: NCT00528047
Drug: PRLX 93936
RxNorm normalized name: PRLX 93936
DrugBank: PRLX 93936 (DB06098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRLX 93936 will be administered intravenously over one hour daily for 5 days.
Trial: NCT04777227
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% (20mg/ml) lidocaine solution
Trial: NCT04777227
Drug: Physiological water injection
RxNorm normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sterile sodium chloride water
Trial: NCT02397512
Drug: application of lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will ingest 50g of lactulose once
Trial: NCT02350023
Drug: Topical latanoprost 0.005%
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Local application of the drug on affected skin/scalp
Trial: NCT02350023
Drug: Topical betamethasone 0.05%
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local application of the drug on affected skin/scalp
Trial: NCT03153163
Drug: Trastuzumab Emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
Trial: NCT01622673
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Trial: NCT00305474
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
Trial: NCT00659451
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets; 50, 100 mg; od; 12 months
Trial: NCT00659451
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets; 5, 10 mg; od; 12 months
Trial: NCT02847260
Drug: Remodulin
RxNorm normalized name: Remodulin
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
Trial: NCT00929968
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00443729
Drug: Comparator: raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
Trial: NCT00443729
Drug: Comparator: lopinavir (+) ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
Trial: NCT02748304
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sorafenib 400mg bid po
Trial: NCT02748304
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin 100mg qd po
Trial: NCT00443690
Drug: rolofylline
RxNorm normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rolofylline 30 mg IV QD; 3 days
Trial: NCT02969252
Drug: Rifamycin SV-MMX® 600
DrugBank: Rifamycin (DB11753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00618111
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03597295
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
Trial: NCT01841684
Drug: Anacetrapib
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet orally, once daily for 12 weeks
Trial: NCT04810208
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel in NanoZolid formulation, for intratumoural injection
Trial: NCT02090088
Drug: Not applicable- observational study
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00659711
Drug: Januvia (Sitagliptin) 100 mg
RxNorm normalized name: Januvia
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The first group will be started on 100 mg sitagliptin daily for 12 weeks
Trial: NCT02426502
Drug: conversion of non-immunosuppressant drugs to once daily
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~* Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative.
Trial: NCT02426502
Drug: Conversion to once daily MPA
RxNorm normalized name: polyurethane-34 (55 MPA)
DrugBank: Urethane (DB04827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~* Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~* Patients taking azathioprine will be maintained on the same dose.~* Patients will be maintained on the same prednisone dose.
Trial: NCT00940628
Drug: orlistat [Xenical]
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120mg po tid
Trial: NCT03963193
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.
Trial: NCT03963193
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.
Trial: NCT02716961
Drug: Gemcitabine, cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
Trial: NCT01380561
Drug: asimadoline
RxNorm normalized name: Asimadoline
DrugBank: Asimadoline (DB05104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
Trial: NCT03932513
Drug: inarigivir soproxil
RxNorm normalized name: Inarigivir soproxil
DrugBank: Inarigivir soproxil (DB15063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inarigivir 200mg and 400mg oral tablets, once daily
Trial: NCT02840929
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03177824
Drug: Sildenafil Citrate 25Mg Tab
RxNorm normalized name: SILDENAFIL CITRATE 25MG TAB
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
Trial: NCT00199420
Drug: Istradefylline (KW-6002)
RxNorm normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03405831
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks
Trial: NCT04464174
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Trial: NCT04464174
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
Trial: NCT04464174
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
Trial: NCT04464174
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
Trial: NCT04369391
Drug: moxifloxacin 400 mg
RxNorm normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: moxifloxacin tablet 400 mg
Trial: NCT01797874
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Experimental
Trial: NCT00517504
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 1-week single blind placebo lead-in phase.~* step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.~Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.~After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control.
Trial: NCT01974622
Drug: Visudyne
RxNorm normalized name: Visudyne
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Half fluence verteporfin
Trial: NCT02015728
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
Trial: NCT02015728
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
Trial: NCT02015728
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is a broad-spectrum kinase inhibitor.
Trial: NCT02015728
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus is an mTOR pathway inhibitor.